Skip to main content
SpringerLink
Log in

Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanyl

  • Hot Topics
  • Published:
Neuropsychopharmacology Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pergolizzi JV Jr, Dahan A, Ann LeQuang J, Raffa RB. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. J Clin Pharm Ther. 2021;46:1501–04.

    Article  CAS  PubMed  Google Scholar 

  2. Drug Enforcement Adminsitration. The growing threat of xylzine and its mixture with illicit drugs. U.S. Department of Justice: Drug Enforcemennt Administration. 2022. https://www.dea.gov/sites/default/files/2022-12/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf. Accessed on June 2023.

  3. Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, et al. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond AS, et al. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine/naloxone. Am J Addict. 2021;30:83–87.

    Article  PubMed  Google Scholar 

  5. Khatri S, Sadek S, Kendrick PT, Bondy EO, Hong M, Pauss S, et al. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. Exp Clin Psychopharmacol. https://psycnet.apa.org/record/2023-92010-001.

Download references

Funding

The authors are supported by DA046526, DA055879, DA058933, and DA049130 (to CDG), and DA055634 (to JCS).

Author information

Authors and Affiliations

  1. Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA

    Cassandra D. Gipson

  2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Justin C. Strickland

Authors
  1. Cassandra D. Gipson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Justin C. Strickland
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CDG wrote the initial draft of the Hot Topic piece, and JCS contributed additional text. Both CDG and JCS edited the manuscript and approved the final version.

Corresponding authors

Correspondence to Cassandra D. Gipson or Justin C. Strickland.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gipson, C.D., Strickland, J.C. Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanyl. Neuropsychopharmacol. 49, 319–320 (2024). https://doi.org/10.1038/s41386-023-01680-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41386-023-01680-7

  • Springer Nature Switzerland AG

Search

Navigation